Saama, iNDX.Ai launch COVID-19 Command Center analytics platform

By Jenni Spinner

- Last updated on GMT

(Image: Getty/Eugeneonline)
(Image: Getty/Eugeneonline)

Related tags: COVID-19, Coronavirus, Saama Technologies, data analysis

The technology offers data analytics capabilities specific to the research and development of therapies targeted at the virus.

The COVID-19 Command Center analytics platform combines Saama Technologies’ Life Science Analytic Cloud (LSAC) and iNDC.Ai’s iCore clinical analytics platforms. The solution is intended to help various life-science companies accelerate internal R&D programs for creating treatments and preventatives for the virus behind the pandemic.

Suresh Katta, founder and CEO of Saama Technologies, said the company is interested in ensuring companies across the industry have access to technology and information to help their research efforts.

Saama wants all life science companies, whether they are engaged in public or private research efforts, to have access to the best possible analytics platform so they can expedite promising COVID-19 clinical trials and bring critical vaccines and treatments to the market as soon as possible​,” he said. “The COVID-19 Command Center, the first offering from Saama’s purpose-built Command Center strategy, is customized to meet immediate needs related to research on the novel coronavirus, but can also be used more broadly for other infectious disease clinical development efforts now and in the future​.”

Last month, Saama Technologies announced the establishment of the EndPandemic National Data Consortium​; both it and iNDX.Ai are members. The collaborative group is intended to harness data pulled from COVID-19 trials to help speed the development and availability of therapies.

According to Saama Technologies, the aim of the COVID-19 Command Center is to give  sponsors conducting in-house COVID-19 clinical development access to an AI-powered data analytics platform. The platform includes patient data from ongoing COVID-19 clinical trials in China, South Korea, and the US, incorporating data from nearly 8,500 patients, including more than 3,000 positive cases.

The COVID-19 Command Center is engineered to provide the multiomics and clinical data analytics necessary to manage COVID-19 clinical studies. From preclinical development to approval, researchers will be able to optimize study design, patient selection, site activation and scientific analysis by dynamically visualizing, analyzing, and interrogating data efficiently.  

Mohan Uttarwar, CEO of iNDX.Ai, said his company believes that AI-empowered data analytics will be useful in accelerating clinical research in trials to help deliver potential COVID-19 treatments.

The COVID-19 Command Center ensures that every life science company, whether engaged in solo or collaborative research, will be able to apply state-of-the-art data analytics to inform and advance their research and help end the pandemic​,” he said. “By partnering on the COVID-19 Command Center, iNDX.Ai and Saama provide an end-to-end clinical development solution, from in silico biomarker discovery to Investigational new drug application submission​.”

Related news

Show more

Related products

show more

SmartSignals Study Oversight

SmartSignals Study Oversight

Signant Health | 24-Jan-2022 | Product Brochure

Today, sponsors and study teams often struggle to support the growing variety and volume of clinical data. The right technology thought will help your...

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more